The American biotechnology company Moderna announced that its vaccine against the emerging corona virus (Covid-19) was “very effective” in children and adolescents between the ages of 12 and 17 years, according to the results of full clinical trials.
The company said it plans to apply for permission to use its vaccine for this age group in early June from regulators around the world.
The vaccine, “Pfizer / Biontec”, has been approved for use in this age group in many countries, including the United States.
“We are relieved that the vaccine has been shown to be highly effective in preventing Covid-19 in young adults. We will report these results to the Food and Drug Administration and regulators around the world in early June and seek permission,” said Stephan Bancel, president of Moderna, in a statement.
Moderna’s study included more than 3,700 participants between the ages of 12 and 17 in the United States, two-thirds of whom received the vaccine and the other third received a placebo.
Moderna said in a statement: “After two doses, no case of Covid was observed in the group that received the vaccine, compared to 4 cases in the placebo group, which means that the vaccine is 100% effective 14 days after the second dose.”
After the first dose, an efficacy of 93% was observed, according to the company, which said that the vaccine was “generally well tolerated” and “no safety concerns have been identified yet.” The side effects were the same as those observed in adults, including pain at the injection site, fatigue and chills.
Follow our latest local and sports news, and the latest political and economic developments via Google news